Teva and Fosun Pharma partner on early-stage oncology drug
The candidate is being evaluated as both a monotherapy and in combination pembrolizumab
Read More
Tag: Shanghai Fosun Pharmaceutical
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
